Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Retirement Systems of Alabama

Retirement Systems of Alabama grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 0.3% in the 4th quarter, HoldingsChannel reports. The firm owned 116,145 shares of the biotechnology company’s stock after purchasing an additional 299 shares during the quarter. Retirement Systems of Alabama’s holdings in Sarepta Therapeutics were worth $14,122,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Wellington Management Group LLP boosted its holdings in Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after purchasing an additional 665,087 shares during the period. Erste Asset Management GmbH purchased a new stake in Sarepta Therapeutics during the 3rd quarter worth about $79,425,000. Janus Henderson Group PLC raised its position in Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after purchasing an additional 543,143 shares in the last quarter. Soros Fund Management LLC purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at about $25,800,000. Finally, Swedbank AB acquired a new position in shares of Sarepta Therapeutics during the fourth quarter worth about $16,706,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Guggenheim raised their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Royal Bank of Canada reiterated an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, Evercore ISI decreased their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.71.

Insider Transactions at Sarepta Therapeutics

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $111.82 on Friday. The stock’s 50-day moving average price is $121.12 and its 200 day moving average price is $126.11. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $10.68 billion, a PE ratio of 89.46 and a beta of 0.75. Sarepta Therapeutics, Inc. has a 52-week low of $102.15 and a 52-week high of $173.25.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.